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ABSTRACT
Objectives Transparent reporting of trials is necessary to 
assess their internal and external validity. Currently, little 
is known about the quality of reporting in antibiotics trials. 
Our study investigates the reporting of adverse events, 
conflicts of interest and funding information in trials of 
penicillins, cephalosporins and macrolides.
Design A secondary analysis of trials included in a 
convenience sample of three systematic reviews.
Methods All randomised controlled trials included in the 
systematic reviews were included, although duplicates 
were removed. Eligible trials compared the specified 
antibiotics to placebo, for any indication. Author pairs 
independently extracted the data on reporting of adverse 
events from parent reviews, and data on funding and 
conflict of interest information from the trial reports. 
We calculated the overall proportion of trials reporting 
adverse events, conflict of interest information and funding 
information, and their proportion before and after the 
publication of the Consolidated Standards of Reporting 
Trials (CONSORT) 2001 Statement.
Results We included 432 trials. Overall, 62% of trials 
reported adverse events of any kind, although reporting 
of deaths or antibiotic resistance was less frequent (20% 
and 37%, respectively). Conflict- of- interest information 
was provided in 26% of the trials, and funding information 
was provided in 66% of the trials. There was no significant 
difference in reporting of adverse events before and 
after the publication of CONSORT 2001 Statement (62% 
vs 62%, p=0.92). Conflict of interest statements were 
provided more frequently (2% vs 55%, p<0.001) and 
conflict was present more often (0% vs 14%, p<0.001). 
There was no difference in the provision of the information 
about trial funding before (62%) and after (70%) CONSORT 
2001 publication.
Conclusions Information about adverse events, conflict 
of interest and funding, remains under- reported in trials of 
antibiotics.
INTRODUCTION
Randomised controlled trials (RCTs) are 
considered the gold standard in evaluating 
the effectiveness of new healthcare inter-
ventions.1 2 However, RCTs have frequently 
been criticised for poor reporting of harms 
or adverse events.3 4 Concerns have also been 
raised about the inadequacy of reporting of 
conflicts of interests and funding informa-
tion, as those may influence—or appear to 
influence—trial design, its conduct, reporting 
of results, their interpretation and conclu-
sions,5–12 in turn jeopardising public trust.13
A clear and transparent reporting of 
studies is therefore needed to assess both 
their internal and external validity.14 To 
improve the quality of RCT reporting, the 
Consolidated Standards of Reporting Trials 
(CONSORT) Statement was first published 
in 1996,15 with two revisions, in 200116 and in 
2010,14 to reflect the evolving consensus on 
the importance of reporting of elements of 
RCTs.
The 1996 CONSORT Statement did 
not include items requiring the reporting 
of adverse events, funding or conflicts of 
interest.15 The 2001 update included an addi-
tion of an adverse events item on the reporting 
checklist, recommending that ‘all important 
adverse events or side effects in each interven-
tion group’ be reported.16 Although neither 
funding nor conflict of interest (COI) infor-
mation was not listed among the reporting 
Strengths and limitations of this study
 ► We analysed the reporting of adverse events, 
conflicts of interests and funding information in 
published antibiotic trials, overall, and before and 
after publication of the Consolidated Standards of 
Reporting Trials 2001 Statement.
 ► The dataset consists of 432 randomised controlled 
trials of antibiotics, conducted across a period of 50 
years, without language or publication restrictions.
 ► Because the data set are limited to three classes of 
antibiotics (macrolides, cephalosporins and penicil-
lins), the conclusions may not be generalisable to 
other classes of antibiotics.
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items, information about sources of funding of the trial 
was identified in the article as highly desirable, and its 
inclusion in an RCT report was encouraged.16
Although several studies have assessed the quality 
of reporting funding resources and conflicts of inter-
ests,17–19 little is known about the quality of reporting of 
antibiotics trials. In this study, we, therefore, investigated 
the reporting in trials of three commonly used antibi-
otic classes: penicillins, cephalosporins and macrolides. 
We focused on the reporting of adverse events, conflicts 
of interests and funding information, both overall, and 
before and after the CONSORT 2001 Statement.
METHODS
Data set
This is a secondary analysis of RCTs included in a conve-
nience sample of three systematic reviews conducted by 
our research group. We choose these reviews as their 
main objective was to analyse the adverse events associ-
ated with the use of the most commonly used antibiotics. 
These systematic reviews included trials of penicillin, 
cephalosporin, or macrolides antibiotics, that compared 
each class alone against a placebo arm, for any indication 
(excluding trials with combined therapy).20–22 The ceph-
alosporin review protocol was withdrawn as the review 
authors did not finish it during the expected time frame, 
along with some administrative issues just before publica-
tion. However, as three of this study authors were coau-
thors of the review, they retrieved all the RCTs included 
in this review (final search date was January 2019). Data 
were extracted from the review and the authors used it for 
this study (eg, reporting of adverse events and resistant 
data).
All RCTs included in the systematic reviews were 
eligible for this study, although duplicates (ie, the same 
RCT included in more than one systematic review) were 
excluded. The Participant, Intervention, Comparator 
and Outcome characteristics of the included systematic 
reviews and trials are summarised in table 1.
Procedure
Author pairs (KY, RN, AMS, MB and JB) independently 
extracted and entered data into a prepiloted data 
extraction form. All discrepancies were resolved by refer-
ence to a third author. Data on reporting of adverse 
events were extracted from the systematic reviews, which 
categorised adverse events as: reported, not reported or 
unclear. For the present analysis, we considered ‘unclear’ 
reporting of adverse events as not reporting.
Data on COI and funding statements were extracted 
directly from the trial reports. As defined per the Inter-
national Committee of Medical Journal Editors (ICMJE), 
COIs included: current or former board membership, 
industry employment, consultancy work, grants (finan-
cial or in- kind), royalties, stock, travel reimbursement 
or other relations with relevant pharmaceutical compa-
nies.23 Funding statements included such information—
whether financial or in kind (eg, supply of drug)—found 
in the article. Conventional funding statements (eg, 
‘this study was funded by a grant from an XYZ organisa-
tion’) were included; statements about in- kind provision 
of pharmaceuticals for the trial by its manufacturer, for 
example, were also included.
Analysis
Data were analysed using Microsoft Excel (Microsoft, 
Redmond, Washington, USA) and descriptive statistics 
were calculated. We calculated the proportion of trials 
reporting or not reporting adverse events, which: (1) 
provided a COI statement; (2) identified a present COI; 
(3) provided a funding statement; (4) stated whether the 
trial was funded; (5) provided information on the source 
of trial funding and (6) identified the funder’s role in the 
trial.
We calculated the proportion of trials up to and 
including 2001 (the year of publication of CONSORT 
2001), and the proportion of trials published from 2002, 
which reported: (1) any adverse events (other than deaths 
or antibiotic resistance); (2) deaths; (3) antibiotic resis-
tance; (4) COI statement; (5) identified an existing COI 
among the trial authors and (6) provided information on 
Table 1 PICO characteristics of the included systematic reviews and trials.
Systematic review (SR) Participants Interventions*, †, ‡ Comparator Outcome
Penicillins20 Individuals of all ages Any penicillin class 
antibiotic
Placebo† Any reported drug- 
related adverse event, 
death, resistant 
bacteria§
Cephalosporins22 Any cephalosporin class 
antibiotics
Macrolides21 Any macrolide class 
antibiotics
*Interventions delivered by any route, including oral, topical, intravenous and intramuscular.
†The use of concomitant medications was permitted if it was given for both arms.
‡Macrolides SR included trials with more than two intervention arms as long as one arm was a macrolide arm and one was a placebo arm.
§Same antibiotic- resistant bacteria for each review.
PICO, Participant, Intervention, Comparator and Outcome.
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the source of trial funding. We chose CONSORT 2001 
rather than the ICMJE disclosure form publication in 
2009 as the cut- point for the before and after analysis, as 
the former is specific to issues in reporting of RCTs, while 
the latter is study type independent.
The χ2 test was used to test for significant differences in 
reporting before and after CONSORT Statement.
Patient and public involvement
Neither patients nor public were directly involved in the 
conduct or writing of this work.
RESULTS
We included 432 RCTs after removing duplicates 
(figure 1). See online supplemental appendix 1 for the 
complete list of included trials.
Summary of reporting characteristics
Overall, 62% of the 432 RCTs reported adverse events; 
reporting was less common specifically for deaths (20%) 
and antibiotic resistance (37%). COI statement was 
provided by 26% of all trials, and a COI was present in 
7%. Funding information was provided in 66% of trials, 
and most commonly, the funding was provided by the 
industry (43%). Statement about the funder’s role in 
the trial was provided by nearly half (49%) of all trials 
(table 2).
Among trials that did report any type of adverse events 
(n=344), 27% provided a COI statement and COI was 
present in 7%. Most trials provided a funding statement 
(69%), and 66% were funded—most frequently by the 
industry (45%). Just over half (52%) of the trials indi-
cated the funder’s role in the trial (table 2).
Of the trials that did not report any type of adverse 
events (n=98), 22% provided a COI statement, and COI 
was present in 4% of the trials. Funding statement was 
provided by 53% of trials, and 51% of the trials were 
funded, most commonly by non- industry (36%). Thirty- 
four per cent of trials provided information about the 
funder’s role in the trial. (table 2)
Reporting before and after CONSORT 2001
The reporting of adverse events—overall, or for deaths 
or antibiotic resistance specifically—did not change 
after the publication of the CONSORT 2001 Statement 
(table 3). Provision of the COI statement increased from 
2% to 55% of the trials after 2001 (p<0.001), and COIs 
became more pervasive, increasing from 0% to 14% after 
2001 (p<0.001). There was a non- significant increase in 
provision of the funding statement, from 62% to 70% 
after 2001 (p=0.077) (table 3).
DISCUSSION
We found that overall, nearly 40% of antibiotics trials did 
not report any adverse events, and there was no change 
in reporting of adverse events before and after the publi-
cation of the CONSORT Statement in 2001. Reporting of 
antibiotic resistance slightly (although non- significantly) 
decreased. Nearly three- quarters of the trials failed to 
provide the COI statement (74%). While 45% of the 
included trials were industry funded, only 7% reported 
a COI. Although there was a significant increase in its 
provision after the publication of the CONSORT State-
ment. Funding statements were provided by two- thirds of 
the trials overall, although no increase was observed after 
CONSORT.
Our findings are consistent with analyses of COI 
reporting in other areas. A study of 444 RCTs of surgical 
interventions found, similarly, that 79% of trials did not 
provide a COI statement, and there was a trend towards 
increase on its provision from 0% (of the trials conducted 
between 1985 and 1994) to 33% (of the trials conducted 
between 2005 and 2014).10 Fewer than half of 848 studies 
in supportive and palliative oncology provided COI infor-
mation, although there was an increase in reporting, 
from 39% of studies in 2004 to 55% in 2009.7 However, 
funding information was provided in only 41% of the 
studies. An analysis of 374 studies in critical care also 
showed a trend towards increased reporting of conflicts 
of interest (from 4% of studies in 2001 to 84% in 2016),6 
and in reporting of funding (from 17% to 59%, respec-
tively). Why funding information provision in supportive 
and palliative oncology, or critical care, is lower than in 
trials of antibiotics (66%) is unclear.
Our finding of poor reporting of death is consistent 
with the results of a similar study that analysed a random 
sample of trials.24 This study of 500 randomly selected 
records in Clinical Trial registry found, similarly, that only 
123 records (25%) reported the number of deaths.
We are unaware of previous analyses of trends around 
the reporting of adverse events of antibiotics over time. 
However, their continued under- reporting is particularly 
concerning, in light of the estimates that deaths attrib-
utable to antibiotic resistance may rise to 10 million per 
annum by 2050.25
Our study has several limitations. We analysed only the 
published trials previously included in our convenience 
sample of three systematic reviews, potentially limiting 
generalisability to other classes of antibiotics and other 
non- published trials. However, the included RCTs trialled 
antibiotics for a large variety of indications and in a wide 
range of settings. We also relied on the original systematic 
reviews’ reporting of adverse events in the original trials, 
Figure 1 Flow diagram of included trials. *Cephalosporin 
Cochrane review is currently unpublished.
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Table 2 Reporting of adverse events, COI and funding by the included RCTs (N=432)
Any type of adverse event
All trials
Reported (n=334) Not reported (n=98) (n=432)




Drug- related adverse events reported (other 
than death / antibiotic resistance)
Yes 266 80 266 62
No* 44 13 142 33
Unclear 24 7 24 5
Deaths reported
Yes 87 26 87 20
No 247 74 345 80
Antibiotic- resistance reported
Yes 158 47 158 36.6
No 173 52 271 62.7
Unclear 3 1 3 0.70%
COI COI statement provided?
Yes 90 27 22 22 112 26
No 244 73 76 78 320 74
COI present?
Present 24 7 4 4 28 7
Absent 66 20 18 18 84 19
Unclear (no COI statement provided) 244 73 76 78 320 74
Funding Funding statement provided?
Yes 231 69 52 53 283 66
No 103 31 46 47 149 34
Was the study funded?
Yes 221 66 50 51 271 63
No 10 3 2 2 12 3
Unclear (no funding statement provided) 103 31 46 47 149 34
Source of funding?†, ‡
Industry 100 45 17 34 117 43
Non- industry 66 30 18 36 84 31
Both (industry and non- industry) 54 25 15 30 69 26
Statement about the funder’s role provided?§
Industry
Yes
No 53 53 5 29 58 50
Non- industry 47 47 12 71 59 50
Yes
No 19 29 2 11 21 25
Both (industry and non- industry) 47 71 16 89 63 75
Yes 43 80 10 67 53 77
No 11 20 5 33 16 33
*Funding body involvement included, but not limited to, drug supply, laboratory services, study co- ordination and monitoring.
†The denominator here is for the number funded studies per each group.
‡The source of funding was not clear for one study
§The denominator here is for the total number of studies per each source of funding group.
COI, conflict of interest; RCT, randomised controlled trial.
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which may have introduced errors, although two of the 
present authors (CDM and AMS) were also involved in 
conducting those systematic reviews. Although it would 
have been interesting to analyse the COI and funding 
reporting by individual journals, it was impossible to do 
so as their policies change over time and it would have 
been difficult to identify which policy was in effect at each 
trial’s publication date. Finally, the results from the macro-
lides trials (n=183) may bias the results towards better 
reporting of COI and funding as they are a newer class of 
antibiotics, compared with cephalosporins and penicillin. 
The strengths include the large number of included trials 
(n=432) covering three of the most commonly prescribed 
antibiotic classes, and a 50- year period covered by the 
trials (1969–2018). The trials included in the analysis 
were not restricted by language or publication (eg, lower 
vs higher impact factor journals). Extraction of data on 
COI and funding from the included RCTs was conducted 
independently by two pairs of authors, and accuracy was 
checked by a third author.
CONCLUSIONS
Our study suggests that information about adverse events, 
conflicts of interest and funding remains under- reported 
in antibiotics trials. The lack of change in reporting 
of adverse events, and the small decrease in reporting 
of antibiotic resistance are concerning, although may 
shift in the coming years by adequately reporting the 
protocols of clinical trials by using Standard Protocol 
Items for Randomised Trials checklist,26 27 and by the 
adoption of checklists specific to reporting antibiotic 
resistance in prospective studies of antibiotic use, such 
as the checklist developed by several authors of the 
present study.28 Pervasiveness of conflicts of interest and 
funding in trials of antibiotics is unsurprising, as RCTs 
are expensive to conduct, and public funding sources 
are limited. However, their presence needs to be trans-
parently reported, so that physicians, patients and other 
stakeholders can consider that information in assessing 
the evidence. An additional benefit would be a positive 
flow- on effect on systematic reviews of primary studies, 
which currently infrequently report the funding sources 
for included RCTs,11 despite requirement that this infor-
mation be provided for studies included in the review.29 
Much work remains to be done by research funders, 
journal editors, clinical trial registries and other research 
outlets to require and clearly convey this information 
to consumers of research, although the trends towards 
Table 3 Reporting adverse events, COI and funding before and after consort 2001 by included studies (N=237 and 195, 
respectively)
Reporting
Studies up to 2001 
(inclusive)
(n=237)
Studies from 2002 
(inclusive)
(n=195) Significance of 
differenceN % N %
Adverse events 
reporting
Drug- related adverse events reported (other 
than death/antibiotic resistance)
Yes 146 62 121 62
No* 91 38 74 38 p=0.92
Deaths reported
Yes 45 19 42 22
No* 192 81 153 78 p=0.51
Antibiotic resistance reported
Yes 93 39 65 33
No 144 61 130 67 p=0.21
COI COI statement provided?
Yes 5 2 107 55
No 232 98 88 45 p<0.001
COI present?
Present 1 0 27 14
Absent 4 2 80 41
Unclear (no COI statement provided) 232 98 88 45 p<0.001
Funding Funding statement provided?
Yes 146 62 136 70
No 91 38 59 30 p=0.077
*Trials whose reporting of adverse events was unclear were included in the ‘not reported’ category
COI, conflict of interest.
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increased reporting over time in antibiotics and other 
areas are encouraging.
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